|
1) Corradini P, Dodero A, Farina L, et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia. 2007; 21: 2316-23
|
|
|
|
2) Kusumi E, Kami M, Kanda Y, et al. Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan. Bone Marrow Transplant. 2005; 36: 205-13
|
|
|
|
|
|
3) Lowsky R, Takahashi T, Liu YP, et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med. 2005; 353: 1321-31
|
|
|
|
|
|
4) Baron F, Storb R, Storer BE, et al. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol. 2006; 24: 4150-7
|
|
|
|
|
|
5) Kim SW, Tanimoto TE, Hirabayashi N, et al. Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. Blood. 2006; 108: 382-9
|
|
|
|
|
|
6) Khouri IF, Saliba RM, Hosing CM, et al. Autologous stem cell (AUTO) vs non-myeloablative allogeneic transplantation (NMT) after high-dose rituximab (HDR) -containing conditioning regimens for relapsed chemosensitve follicular lymphoma (FL). Blood (ASH Annual Meeting Abstracts). 2005; 106: 48
|
|
|
|
|
|
7) Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet. 2005; 365: 1934-41
|
|
|
|
|
|
8) Devetten MP, Hari P, Carerras J, et al. Unrelated donor nonmyeloablative/reduced intensity (NST/RIC) hematopoietic stem cell transplantation (HCT) for patients with relapsed and refractory Hodgkin's lymphoma (HL). Blood (ASH Annual Meeting Abstracts). 2006; 108: 601
|
|
|
|
|
|
9) Gopal AK, Rajendran JG, Gooley TA, et al. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults ＞ or ＝ 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol. 2007; 25: 1396-402
|
|
|
|
|
|
10) Gopal AK, Rajendran JG, Pagel JM, et al. A phase II trial of 90Y-ibritumomab tiuxetan-based reduced intensity allogeneic peripheral blood stem cell (PBSC) transplantation for relapsed CD20＋ B-cell non-Hodgkin's lymphoma (NHL). Blood (ASH Annual Meeting Abstracts). 2006; 108: 316
|
|
|
|
|
|
11) Khouri IF, SalibaRM, Hosing C, et al. Efficacy and safety of yttrium 90 (90Y) ibritumomab tiuxetan in autologous and nonmyeloablative stem cell transplantation (NST) for relapsed non-Hodgkin's lymphoma (NHL). Blood (ASH Annual Meeting Abstracts). 2006; 108: 315
|
|
|
|
|
|
12) Fietz T, Uharek L, Gentilini C, et al. Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan. Leuk Lymphoma. 2006; 47: 59-63
|
|
|
|
|
|
13) Khouri IF, Saliba RM, Lee MS, et al. Longer follow-up confirms a low relapse rate after non-myeloablative allogeneic transplantation (NMT) for non-Hodgkin's lymphoma (NHL), including patients with PET or gallium-avid disease. Blood (ASH Annual Meeting Abstracts). 2005; 106: 44
|
|
|
|
|
|
14) Thomson KJ, Morris EC, Milligan D, et al. Reduced intensity allogeneic transplantation for non-Hodgkin's lymphoma: extended follow-up of an alemtuzumab-containing regimen. Blood (ASH Annual Meeting Abstracts). 2005; 106: 401
|
|
|
|
|
|
15) Van Besien K, Carreras J, Zhang MJ, et al. Reduced intensity vs myeloablative conditioning for HLA matched sibling transplantation in follicular lymphoma. Blood (ASH Annual Meeting Abstracts). 2005; 106: 656
|
|
|
|
|
|
16) Avivi I, Canals C, Taghipour G, et al. Matched unrelated donor stem cell transplantation for patients with diffuse large cell B cell lymphoma: a retrospective analysis of 118 patients registered through the European Group for Blood and Marrow Transplantation (EBMT). Blood (ASH Annual Meeting Abstracts). 2006; 108: 602
|
|
|
|
|
|
17) Thomson KJ, Peggs KS, Smith P, et al. Improved outcome following reduced intensity allogeneic transplantation in Hodgkin's lymphoma relapsing post-autologous transplantation. Blood (ASH Annual Meeting Abstracts). 2005; 106: 657
|
|
|
|
|
|
18) Law L, Horning S, Wong R, et al. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2006; 12: 703-11
|
|
|
|
|
|
19) Aksentijevich I, Jones R, Ambinder R, et al. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2006; 12: 965-72
|
|
|
|
|
|
20) Feyler S, Prince HM, Pearce R, et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant. 2007; 40: 443-50
|
|
|
|
|
|
21) Wulf GG, Hasenkamp J, Jung W, et al. Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma. Bone Marrow Transplant. 2005; 36: 271-3
|
|
|
|
|